Feb 28, 2017
MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. concludes a patent licensing agreement with the University of Toyama concerning a rapid antibody production technique
Nagoya, Japan – February 28, 2017 - MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. (MBL) and the University of Toyamaannounced today that they have entered a patent licensing agreement for the Magnetic-beads Reaction through Arrayed Hanging-Droplets method (MAGrahd method), a rapid antibody production technique invented by the University of Toyama. The MAGrahd method reliably allows for the synthesis of an antibody gene from a single antibody-producing cell. Through the agreement, MBL has acquired the rights to develop and create high-performance antibodies using the MAGrahd method worldwide. >> PDF: 30KB
Jan 27, 2015
Medical and Biological Laboratories Co., Ltd., establishes MBL Europe
Medical & Biological Laboratories, Co., Ltd. (Jun Sasaki, President and C.E.O., with Headquarters in Nagoya, Aichi, Japan), has announced the opening of our MBL Europe office in Diegem (Mechelen), Belgium as a new liaison/representative office. >>PDF: 56KB
Jun 19, 2014
CE Mark of a novel reagent to detect RAS (KRAS and NRAS) gene mutations for testing of anti-EGFR therapeutic antibodies to colon cancer prior to treatment.
MBL International Corporation (MBLI), headquartered in Woburn, MA, Medical and Biological Laboratories Co., Ltd. (Nagoya, Aichi, Japan) and G&G Science (Fukushima, Fukushima, Japan), a subsidiary company, jointly developed a novel reagent to detect RAS (KRAS and NRAS) gene mutations for determination of anti-epidermal growth factor receptor (EGFR) therapeutic antibodies prior to treatment on the basis of a recent clinical finding. We submitted the application for CE mark for the reagent in Europe (Description : MEBGEN™ RASKET KIT) on June 13, and have also submitted the application for the manufacture and sales approval as an in vitro diagnostic to the Pharmaceuticals and Medical Devices Agency in Japan. >>PDF: 59KB
Jun 10, 2014
MBL International Corporation opens a new R&D laboratory.
MBL International Corporation (MBLI), headquartered in Woburn, MA, USA, a wholly owned company of Medical & Biological Laboratories, Co., Ltd. in Japan in collaboration with SCIVAX USA, has announced opening a new R&D laboratory. >>PDF: 39KB
Dec 04, 2012
MHC tetramer reagents and infectious disease, cancer antigen epitope identification reagents: worldwide business transfer for development, manufacturing and distribution
Medical & Biological Laboratories Co., Ltd. (MBL) announces it concluded a comprehensive agreement with Beckman Coulter, Inc. (BCI) to transfer BCI's worldwide business of development, manufacturing, and distribution of MHC tetramer reagents and infectious disease, cancer antigen identification reagents to MBL. >>
Jun 20, 2011
China National Biotec Group and Medical & Biological Laboratories Co., Ltd. have agreed to a Comprehensive Business Alliance.
Establishment of Business Operations for Clinical Diagnostic Business and Therapeutic Monoclonal
Antibody Development in China.
China National Biotec Group (CNBG) and Medical & Biological Laboratories Co., Ltd. (MBL) have agreed to develop a comprehensive business alliance for clinical diagnostic and therapeutic monoclonal antibody development in China. >>
Feb 12, 2010
Launch of Human Papillomavirus (HPV) Genotyping Reagent -A product enabling simultaneous detection of 31 HPV genotypes, the largest number in Japan-
MBL in collaboration with its subsidiary company, G&G Science Co., Ltd. has successfully developed a human papillomavirus (HPV) genotyping reagent -GENOSEARCH-HPV31- and launches this product. >>
Jan 12, 2010